# A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia

> **NCT03692052** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Agios Pharmaceuticals, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Thalassemia

## Interventions

- **DRUG:** AG-348

## Key facts

- **NCT ID:** NCT03692052
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-20
- **Primary completion:** 2020-08-20
- **Final completion:** 2030-09-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03692052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03692052, "A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03692052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*